

**Listing of the Claims:**

1. (Canceled)

2. (Canceled)

3. (Currently Amended) A method of treating diabetes and/or microvascular diabetic complications comprising administering C-peptide or a pharmaceutical composition comprising C-peptide to a patient once daily; wherein said once daily administration does not include a continuous administration or the presence of release rate-controlling agents, and wherein said administration is by subcutaneous administration, and wherein said pharmaceutical composition contains 100 to 1800 nmol of C-peptide.

4. (Canceled)

5. (Canceled)

6. (Canceled)

7. (Canceled)

9. (Canceled)

10. (Previously Amended) The method according to claim 3, wherein said C-peptide is human C-peptide.

11. (Previously Presented) The method according to claim 3, wherein said C-peptide is a fragment EGSLQ (SEQ ID NO: 2).

12. (Previously Amended) The method according to claim 3, wherein said patient is a human.

13. (Canceled)

14. (Previously Amended) The method according to claim 3, wherein said C-peptide is in an aqueous solution.

15. (Currently Amended) The method according to claim 3 16, wherein said complications are diabetic neuropathy.

16. (New) The method according to claim 3, wherein said complications are diabetic nephropathy, retinopathy or neuropathy.